Page 51 - CPG - Clinical Practice Guidelines - Management of Cancer Pain
P. 51

Management of Cancer Pain (Second Edition)
                  Refer to $SSHQGL[   for *XLGH IRU 1DOR[RQH 8VH.


                  5HFRPPHQGDWLRQ
                  ‡  2SLRLG LQGXFHG  VLGH  HIIHFWV  VKRXOG  EH  SURDFWLYHO\  LGHQWL¿HG  DQG
                    treated adequately to ensure optimum cancer pain management.
                  ‡  /D[DWLYHV  VKRXOG  EH  SURSK\ODFWLFDOO\  SUHVFULEHG  LQ  SDWLHQWV  ZLWK
                    cancer pain and on regular opioid therapy.


                          7ROHUDQFH DQG DGGLFWLRQ WR RSLRLGV
                  ‡   7ROHUDQFH WR RSLRLGV
                  2SLRLG WROHUDQFH LV GH¿QHG DV D ORQJ WHUP ERG\ DGDSWDWLRQ WR RSLRLGV
                  resulting in reduced clinical effectiveness of opioids with repeated use
                  at the same dose. 57

                  Opioid tolerance in cancer is known to  be contributed by  the
                  GRZQUHJXODWLRQ RI PX UHFHSWRUV LQ QHXURQDO FHOOV  7KH H[DFW PHFKDQLVP
                  is still not well understood. Persistent pain, chronic opioid administration
                  DQG UHGXFHG H[SUHVVLRQ RI RSLRLG UHFHSWRUV RQ FHUWDLQ W\SHV RI FDQFHU
                  cells are possible causes of mu-receptor downregulation.
                                                                58
                  Fear  of  opioid tolerance should not  cause any hesitation to  start  or
                  LQFUHDVH RSLRLG WKHUDS\ IRU FDQFHU SDWLHQWV H[SHULHQFLQJ SDLQ  +RZHYHU
                  when opioid doses are very high (oral morphine >600 mg/day,  oral
                  R[\FRGRQH  !     PJ GD\  RU  WUDQVGHUPDO  IHQWDQ\O  !     PFJ KRXU
                  patients should be referred to a pain specialist or palliative medicine
                  specialist. 9

                  ‡   $GGLFWLRQ PLVXVH RI RSLRLGV
                  The incidence  of opioid  misuse in advanced  cancer patients differs
                  widely  between studies in a recent systematic review.  Particularly
                  among children,  adolescents and young adults, misuse behaviours
                  were reported to range from 7% to 90%. 59, level I  1RQVSHFL¿F VXEVWDQFH
                  use disorders were reported to range between 2% to 35% of adults with
                  cancer. It is unclear if this included treatment-related opioid dependence
                  or misuse. 60, level I

                  0XOWLSOH ULVN IDFWRUV IRU RSLRLG PLVXVH RU DEXVH KDYH EHHQ LGHQWL¿HG
                  among patients with cancer e.g: 61
                    {  history of dependence or misuse of prescription drugs, illicit drugs or
                      alcohol prior to cancer diagnosis/treatment
                    {  history of binge drinking (alcohol) or peers who binge drink
                    {  family history of substance abuse
                    {  KLVWRU\ RI SV\FKLDWULF GLVRUGHU LQFOXGLQJ DQ[LHW\  GHSUHVVLRQ  DWWHQWLRQ
                      GH¿FLW  K\SHUDFWLYLW\  GLVRUGHU   SRVW WUDXPDWLF  VWUHVV  GLVRUGHU   ELSRODU
                      disorder or schizophrenia


                                             33




          e-cpg inside text-Cancer pain-25/5/24.indd   33               09/08/2024   12:09 AM
   46   47   48   49   50   51   52   53   54   55   56